Last-Chance brain cancer vaccine offered to desperate patients
NCT ID NCT04802447
Summary
This program provided continued access to an experimental vaccine called SurVaxM for patients with glioblastoma, a serious brain cancer. It was for patients who had no other comparable treatment options or who had already completed a prior SurVaxM trial and wished to keep receiving it. The goal was to help control the disease and potentially extend survival for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.